Advanced search
Publication Cover
OncoTargets and Therapy Volume 16, 2023 - Issue
Submit an article Journal homepage
293
Views
2
CrossRef citations to date
0
Altmetric
CASE REPORT

Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report

Kazuhito Misawa1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, JapanORCID Iconhttps://orcid.org/0000-0002-4948-2245
ORCID Icon,
Shinji Nakamichi1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, JapanCorrespondence[email protected]
,
Hiroki Iida1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, Japan
,
Atsuhiro Nagano1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, Japan
,
Erika Mikami1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, Japan
,
Takehiro Tozuka1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, JapanORCID Iconhttps://orcid.org/0000-0002-3774-8915
ORCID Icon,
Masaru Matsumoto1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, Japan
,
Akihiko Miyanaga1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, JapanORCID Iconhttps://orcid.org/0000-0003-2026-9181
ORCID Icon,
Rintaro Noro1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, Japan
,
Kaoru Kubota1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, Japan
,
Hiroki Yamaguchi2 Department of Hematology, Nippon Medical School, Tokyo, 113-8603, Japan
&
Masahiro Seike1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, 113-8603, Japan
 show all
Pages 65-69 | Received 24 Nov 2022, Accepted 12 Jan 2023, Published online: 24 Jan 2023

References

  • Garbe E, Andersohn F, Bronder E, et al. Drug induced immune haemolytic anaemia in the berlin case-control surveillance study. Br J Haematol. 2011;154:644–653.
  • Petz LD, Garratty G. Drug-induced haemolytic anaemia. Clin Haematol. 1975;4:181–197. doi:10.1016/S0308-2261(21)00631-7
  • Garratty G. Drug-induced immune hemolytic anemia. Hematology. 2009;1:73–79. doi:10.1182/asheducation-2009.1.73
  • Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–1703. doi:10.1056/NEJMoa1006448
  • Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–838. doi:10.1056/NEJMoa1704795
  • Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised Phase 3 trial. Lancet. 2017;390:29–39. doi:10.1016/S0140-6736(17)30565-2
  • Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31:1056–1064. doi:10.1016/j.annonc.2020.04.478
  • Okumoto J, Sakamoto S, Masuda T, et al. Alectinib-induced immune hemolytic anemia in a patient with lung adenocarcinoma. Intern Med. 2021;60(4):611–615. doi:10.2169/internalmedicine.4241-19
  • Kunz J, Wiedemann C, Grosch H, et al. Early development of ubiquitous acanthocytosis and extravascular hemolysis in lung cancer patients receiving alectinib. Cancers. 2022;14(11):2720. doi:10.3390/cancers14112720
  • Kuzich JA, Heynemann S, Geoghegan N, et al. Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding. Pathology. 2021;53(5):608–612. doi:10.1016/j.pathol.2020.10.023
  • Dores GM, Nayernama A, Cheng C, et al. Hemolytic anemia following alectinib reported to the U.S. food and drug administration adverse event reporting system. Am J Hematol. 2022;97(4):E129–E132. doi:10.1002/ajh.26454
  • Yuan Y, Mapp S, Xu W. Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor. Br J Haematol. 2020;190(5):642. doi:10.1111/bjh.16813
  • Gullapalli V, Xu W, Lewis CR, et al. A multi-centre case series of alectinib-related erythrocyte membrane changes and associated haemolysis. J Hematopathol. 2021;14(2):131–136. doi:10.1007/s12308-020-00427-3
  • Legland Ép Dejean AM, Plantamura J, Arnoux I, et al. Acanthocytosis in an alectinib-treated patient. Br J Haematol. 2022;197(2):131. doi:10.1111/bjh.18020
  • Nakagawa K, Hida T, Nokihara H, et al. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020;139:195–199. doi:10.1016/j.lungcan.2019.11.025
  • Dhaliwal G, Cornett PA, Tierney LM Jr. Hemolytic anemia. Am Fam Physician. 2004;69:2599–2606.
  • Crizotinib 2016; Available from: doi:10.1007/s40278-016-23836-6. Accessed January 23, 2023.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.